Press Release-Alphamab Oncology

English 中文简体中文繁体

English 中文简体中文繁体

News Press Release Media Report

Year:

Select

Press Release

05 August 2026

Alphamab Oncology Announces NDA for Anbenitamab (KN026) in Combination with HB1801 as Neoadjuvant Treatment for HER2-Positive Breast Cancer Accepted by NMPA and Granted Priority Review is expected to become a new standard of care for neoadjuvant therapy in HER2-positive early or locally advanced breast cancer
04 August 2026

Alphamab Oncology and Pathos Achieved a Licensing Agreement on TROP2/HER3 Bispecific ADC JSKN016 this collaboration will accelerate the global clinical advancement of JSKN016 and bring a potential breakthrough therapy to more patients with solid tumors
03 August 2026

Alphamab Oncology Announces CDE Approval for Phase III Study of JSKN033, First-in-Class HER2 Bispecific ADC Subcutaneous Co-formulation, in Cervical Cancer The study will compare JSKN033 with physician choice chemotherapy in patients with recurrent or metastatic cervical cancer whose disease has progressed on or after platinum-based chemotherapy and IO t...
15 July 2026

Alphamab Oncology Announces Anbenitamab (KN026) Was Granted Another Breakthrough Therapy Designation for First-line Treatment of HER2-Positive Breast Cancer This is the second BTD for Anbenitamab, following its prior designation in HER2-positive gastric cancer (including gastroesophageal junction adenocarcinoma), further validating its exceptional clinica...
13 July 2026

Alphamab Oncology’s Anbenitamab (KN026) Selected as One of 2026 Suzhou Top Ten Industrial Scientific and Technological Achievements not only highly recognizes Anbenitamab as a front‑runner in HER2 bispecific antibodies, but also serves as an authoritative endorsement of Alphamab’s commitment to addressing clinical needs and purs...
26 June 2026

Alphamab Oncology Once Again Named to “Top 100 Chinese Pharmaceutical Innovative Enterprises” Ranking, with Innovation Strength Consistently Recognized by Industry Authorities The selected enterprises represent the backbone of China’s pharmaceutical innovation landscape and serve as industry benchmarks with a mature innovation ecosystem and robust growth momentum
11 June 2026

Alphamab Oncology Announces the Phase III Clinical Study of Anbenitamab (KN026) Combined with HB1801 as First-line Treatment for Breast Cancer Has Met the Primary Endpoint This is the world’s first head‑to‑head Phase III study of a HER2 bispecific antibody‑based combination therapy that has successfully demonstrated superior efficacy over the THP regimen in first‑l...
03 June 2026

Alphamab Oncology Announces the First Patient Dosed in a Phase I Clinical Study of EGFR/HER3 Dual Payload Bispecific ADC JSKN021 JSKN021 is the company’s sixth ADC candidate entering clinical development, as well as its first dual payload ADC to advance into clinical trials
02 June 2026

2026 ASCO | Alphamab Oncology Presented Clinical Data of TROP2/HER3 Bispecific ADC JSKN016 for HER2-Negative Breast Cancer JSKN016 demonstrated very promising efficacy and superior safety profile in late line HER2-negative BC patients
01 June 2026

2026 ASCO | Alphamab Oncology Announces Results from Phase III Study of Anbenitamab (KN026) Combined with HB1801 in Neoadjuvant Treatment for Breast Cancer Presented at LBA Oral Presentation Session This study is the first Phase III clinical trial worldwide to directly demonstrate that a bispecific antibody has superior efficacy to the combination of two monospecific antibodies targeting the same...